Key Analysts at Citigroup Didn’t Change their ‘”Neutral”’ rating for The Medicines (NASDAQ:MDCO) Shares Today. Their Target Price per Share is Set to $43

July 17, 2017 - By Linda Rogers

 Key Analysts at Citigroup Didn't Change their ‘

Investors sentiment decreased to 1.12 in 2016 Q4. Its down 0.04, from 1.16 in 2016Q3. It is negative, as 33 investors sold The Medicines Company shares while 53 reduced holdings. 25 funds opened positions while 71 raised stakes. 80.06 million shares or 1.63% less from 81.39 million shares in 2016Q3 were reported.

Old West Investment Llc holds 10,493 shares. Partner Fund Mgmt L P accumulated 2.72 million shares. New York-based Bridger Mgmt has invested 3.83% in The Medicines Company (NASDAQ:MDCO). Amer International accumulated 0.01% or 49,702 shares. Us-based Ancora Advisors Limited Liability Company has invested 0% in The Medicines Company (NASDAQ:MDCO). Wellington Group Limited Liability Partnership invested in 9.90 million shares or 0.08% of the stock. The Wisconsin-based Mason Street Advsr Ltd has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Pacad Inv Ltd holds 7,300 shares. 82,134 are held by Guggenheim Ltd. Strs Ohio reported 0% in The Medicines Company (NASDAQ:MDCO). Envestnet Asset Management has 0% invested in The Medicines Company (NASDAQ:MDCO) for 2,376 shares. Us Comml Bank De reported 0% of its portfolio in The Medicines Company (NASDAQ:MDCO). Louisiana State Employees Retirement System, Louisiana-based fund reported 28,000 shares. Integral Derivatives Limited accumulated 21,025 shares. Iguana Healthcare Mgmt Limited Liability Com invested in 275,000 shares.

Since February 3, 2017, it had 0 insider purchases, and 2 sales for $4.07 million activity. Shares for $1.19 million were sold by O’Connor William Bernard on Friday, February 3.

The Medicines (NASDAQ:MDCO) Rating Reaffirmed

Recently, In an analyst note issued to investors and clients on Monday morning, The Medicines (NASDAQ:MDCO) shares have had their “Neutral” Rating reiterated by stock research analysts at Citigroup, who currently has a $43 target on firm. This target by Citigroup gives the possibile upside of 11.92 % from the current stock price.

Investors sentiment decreased to 1.12 in 2016 Q4. Its down 0.04, from 1.16 in 2016Q3. It is negative, as 33 investors sold The Medicines Company shares while 53 reduced holdings. 25 funds opened positions while 71 raised stakes. 80.06 million shares or 1.63% less from 81.39 million shares in 2016Q3 were reported.

Old West Investment Llc holds 10,493 shares. Partner Fund Mgmt L P accumulated 2.72 million shares. New York-based Bridger Mgmt has invested 3.83% in The Medicines Company (NASDAQ:MDCO). Amer International accumulated 0.01% or 49,702 shares. Us-based Ancora Advisors Limited Liability Company has invested 0% in The Medicines Company (NASDAQ:MDCO). Wellington Group Limited Liability Partnership invested in 9.90 million shares or 0.08% of the stock. The Wisconsin-based Mason Street Advsr Ltd has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Pacad Inv Ltd holds 7,300 shares. 82,134 are held by Guggenheim Ltd. Strs Ohio reported 0% in The Medicines Company (NASDAQ:MDCO). Envestnet Asset Management has 0% invested in The Medicines Company (NASDAQ:MDCO) for 2,376 shares. Us Comml Bank De reported 0% of its portfolio in The Medicines Company (NASDAQ:MDCO). Louisiana State Employees Retirement System, Louisiana-based fund reported 28,000 shares. Integral Derivatives Limited accumulated 21,025 shares. Iguana Healthcare Mgmt Limited Liability Com invested in 275,000 shares.

Since February 3, 2017, it had 0 insider purchases, and 2 sales for $4.07 million activity. Shares for $1.19 million were sold by O’Connor William Bernard on Friday, February 3.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Among 7 analysts covering The Medicines Co (NASDAQ:MDCO), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. The Medicines Co has $65 highest and $44 lowest target. $54.38’s average target is 41.54% above currents $38.42 stock price. The Medicines Co had 18 analyst reports since August 28, 2015 according to SRatingsIntel. The stock of The Medicines Company (NASDAQ:MDCO) has “Buy” rating given on Monday, August 31 by Leerink Swann. JP Morgan maintained the shares of MDCO in report on Saturday, August 29 with “Buy” rating. The stock of The Medicines Company (NASDAQ:MDCO) has “Hold” rating given on Wednesday, July 12 by Oppenheimer. RBC Capital Markets maintained the stock with “Outperform” rating in Monday, August 31 report. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, November 16. The rating was maintained by Oppenheimer with “Market Perform” on Monday, August 31. Jefferies maintained it with “Buy” rating and $6200 target in Monday, June 26 report. The firm earned “Buy” rating on Monday, March 21 by Chardan Capital Markets. Chardan Capital Markets initiated The Medicines Company (NASDAQ:MDCO) rating on Wednesday, November 4. Chardan Capital Markets has “Buy” rating and $50 target. RBC Capital Markets maintained The Medicines Company (NASDAQ:MDCO) rating on Tuesday, November 8. RBC Capital Markets has “Outperform” rating and $45 target.

About 500,410 shares traded. The Medicines Company (NASDAQ:MDCO) has risen 16.70% since July 17, 2016 and is uptrending. It has by 0.00% the S&P500.

Investors wait The Medicines Company (NASDAQ:MDCO) to report on July, 26. its quarterly earnings Wall Street analysts expect $-1.24 earnings per share, down $0.40 or 47.62 % from last year’s $-0.84 same quarter earnings. The Medicines Company’s Wall Street analysts see -13.89 % EPS growth, taking into account the $-1.44 EPS reproted in the previous quarter,

The Medicines Company is a global biopharmaceutical company. The company has market cap of $2.80 billion. The Firm is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It currently has negative earnings. It markets Angiomax , Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.